Bioalmanac

Liraglutide

Victoza (brand) · Saxenda (brand) · NN2211

Approved

Status reviewed 16 Aug 2026

The first GLP-1 analogue approved for weight loss. A daily injection, superseded by weekly semaglutide but still the best-documented compound in the class.

Storage

Freeze-dried powder: The approved product is a solution, not a powder. Refrigerated at 2–8 °C before first use.
After mixing: After first use, up to 30 days at room temperature below 30 °C or refrigerated. Protect from light and do not freeze.
Long-term, frozen: Never freeze. Freezing destroys it, and it cannot be used after.

Reconstitution — 18 mg vial, 3000 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water added	Concentration	Volume to draw	Units	Doses per vial
1 mL	18 mg/mL	0.167 mL	16.67 units	6
2 mL	9 mg/mL	0.333 mL	33.33 units	6
3 mL	6 mg/mL	0.5 mL	50 units	6
5 mL	3.6 mg/mL	0.833 mL	83.33 units	6

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

Goal	Range	Frequency	Source
Weight management escalation, as approved	600–3000 mcg	Once daily, increasing by 0.6 mg each week	Clinical trial
Type 2 diabetes, as approved	600–1800 mcg	Once daily	Clinical trial

When to stop

Severe, persistent abdominal pain, particularly radiating to the back. Possible pancreatitis. Stop and seek urgent care.
Pain in the upper right abdomen, fever, or yellowing of the skin or eyes. Possible gallbladder disease. Seek care.
A lump in the neck, hoarseness that does not resolve, or difficulty swallowing. Investigate before continuing.
Vomiting severe enough that you cannot keep fluids down. Dehydration on a GLP-1 can injure the kidneys.
Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
Signs of low blood sugar if you also use insulin or a sulfonylurea: sweating, shaking, confusion. Those doses usually need reducing.

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.